文档介绍：新疆医科大学硕士学位论文
Meta-analysis of randomized placebo-controlled clinical
trials on rasagiline treatment of Parkinson's disease
Postgraduate:Tong Yu-shan Supervisor: Xin-ling
Abstract
Objective:To assess the effectiveness and safety of rasagiline for Parkinson 's
disease.
Methods:Literature databases including cochrane library,Web of
Knowledge(SCI),OVID(Medline),Pubmed,Wanfang KI and VIP,and references
and retrospective literature were date of search was from begining to
October data of RCTs Meeting the inclusive criteria were extracted according to
Cochrane methods by two reviewers independently,and after the quality was
analyzed by software.
Results:A total of six RCTs involving 3269 patients were results of
meta-analysis showed that:a)About pare with placebo,rasagiline 2mg/d
was more effective in the treatment of early PD with significant
differences(WMD=-,95%CI:- to -,P<);compare with rasagiline
1mg/d and 2mg/d in treatment of early PD,a significant differences was
found(WMD=,95%CI: to ,P<).b)About the safety:there was no
significant differences between rasagiline and placebo in the incidence of
nausea’headache and dizziness.
conclusion:Rasagiline is effective of treatment in early Parkinson 's disease , the dosage
1mg/d is better than 2mg/d in treatment of early rasagiline has a well tolerance
and high-quality randomized controlled trials are needed to provide reliable
evidence on the treatment of patients with Parkinson’s disease.
Key words: parkinson's disease; rasagiline; monoamine oxidase type
B inhibitor; randomized controlled trial; meta-analysis
2
万方数据
新疆医科大学硕士学位论文
前言
帕金森病(parkinson's disease;PD)是一种常见的神经系统退行性疾病,呈进行性
发展。各年龄人群均可能发病,但以中老年人为主要患病人群。随着我国人口老龄
化发展,PD 发病率呈逐年上升趋势,并且发病人群呈现年青化趋势,给家庭和社
会带来了沉重的负担。PD 是导致帕金森氏综合征最常见的原因,它影响着约 100
万美国人口,在全球范围约 500 万人口[1]。目前 PD 的病因还不是十分清楚,遗传
和环境因素交互作用可能是主要的原因[2]。PD